BioAge Labs Stock Plummets Over 50% After Novo Nordisk Trial Casts Doubt on Drug Strategy

Shares of BioAge Labs (BIOA) plummeted -51.9% in pre-market trading after drugmaker Novo Nordisk announced disappointing results from a major cardiovascular study, creating a negative read-through for BioAge's lead drug candidate.

The Catalyst: Novo Nordisk's ZEUS Trial Fails

Novo Nordisk disclosed that its Phase 3 ZEUS trial for ziltivekimab, an IL-6 pathway inhibitor, failed to meet its primary endpoint. The study, which enrolled patients with atherosclerotic cardiovascular disease and chronic kidney disease, did not show a meaningful reduction in major adverse cardiovascular events compared to a placebo.

According to the announcement, the drug produced a hazard ratio of approximately 1.0, indicating no statistical benefit despite successfully suppressing the targeted IL-6 inflammatory pathway. This outcome raises fundamental questions about the viability of inhibiting upstream inflammation to achieve cardiovascular benefits in this patient population.

Implications for BioAge's Pipeline

The fallout for BioAge Labs is direct and severe because its lead asset, BGE-102, is based on a similar scientific premise. BGE-102, an orally available NLRP3 inhibitor, is currently in a Phase 2 trial, named QUELL-CV, for patients with elevated cardiovascular risk.

Ad

The failure of Novo Nordisk's well-resourced program casts significant doubt on the entire therapeutic strategy. Investors are now reassessing the probability of success for BGE-102, as its mechanism of action is closely related to the one that just failed in a large-scale, late-stage trial.

Market Reaction and Context

The sell-off in BioAge stock was stark and isolated. Prior to the news, shares had been trading near a 52-week high of $25.96, but plunged to $11.96 in pre-market activity. The sharp decline was amplified by the stock's recent strong performance, which was based on optimism for BGE-102's potential.

The drop was not related to broader market trends, as major indices like the S&P 500 and Nasdaq were trading higher. The move underscores investor concern that the scientific foundation for a key part of BioAge's pipeline may be flawed, a risk highlighted by the unexpected failure of a similar drug from a major pharmaceutical company.